|
||||
Total: $185.48M | ||||
|
||||
Company |
Location |
Date |
Amt. (M) |
Details |
|
||||
Affinium Pharmaceuticals Inc. |
Austin, Texas |
8/30 |
$15 |
Affinium raised $15M in a follow-on Series A financing; investors were SV Life Sciences, Genesis Capital Partners and Forward Ventures, as well as Ontario Emerging Technologies Fund |
Autifony Therapeutics Ltd. |
London |
8/23 |
£10 ($16.4) |
Autifony received $16.4M from venture capital investors, including Imperial Innovations plc and SV Life Sciences |
CoLucid Pharmaceuticals Inc. |
Durham, N.C. |
8/31 |
$7.5 |
CoLucid raised $7.5M of a planned $9.5M convertible note financing from its existing investors; participating investors included Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures |
Embera NeuroTherapeutics Inc. |
Shreveport, La. |
8/16 |
$4.5 |
Embera closed a $4.5M round in a continuation of its Series A financings; investors were Louisiana Ventures LP, Louisiana Fund I and Themelios Ventures, as well as private investors |
Enobia Pharma Inc. |
Montreal |
8/11 |
$40 |
Enobia raised $40M in a Series D round with Banc of America Merrill Lynch acting as exclusive placement agent |
Jennerex Inc. |
San Francisco |
8/12 |
$8.6 |
Jennerex completed a private placement of $8.6M |
Mirna Therapeutics Inc. |
Austin, Texas |
8/24 |
$1.5 |
Mirna closed a $1 .5M quity round with participation from several existing shareholders |
Mission Therapeutics Ltd. |
London |
8/25 |
£6 ($9.8) |
Mission raised $9.8M in its first round from Sofinova Partners, Imperial Innovations, SR One and the Roche Venture Fund |
OncoCyte Corp. |
Alameda, Calif. |
8/25 |
$10 |
OncoCyte received $4M in cash and $6M in BioTime Inc. common shares through the financing |
Proteon Therapeutics Inc. |
Waltham, Mass. |
8/15 |
$15.2 |
Proteon raised $15.2M in the Series C round |
Pulmatrix Inc. |
Lexington, Mass. |
8/16 |
$14 |
Pulmatrix pulled in another $14M in a Series B round from 2009; investors were Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund |
SironRX Therapeutics Inc. |
Cleveland |
8/17 |
$3.4 |
SironRX closed a $3.4M Series A invements led by North Coast Angel Fund; additional investors were the Cleveland Clinic, JumpStart Inc., Glengary LLC, Ohio Tech Angel Fund III, Early Stage Partners, X Gen Ltd. and Fletcher Spaght Investments |
Spinifex Pharmaceuticals Pty. Ltd. |
Victoria, Australia |
8/24 |
A$6.25 ($6.58) |
Spinifex closed a $6.58M expanded Series B round; investors were GBS Venture Partners, Brandon Capital, Uniseed and Uniquest |
Thetis Pharmaceuticals LLC |
Rocky Hill, Conn. |
8/24 |
$1.5 |
Thetis received $1.5M in seed funding from Connecticut Innovations, Stonehenge Partners and angel investors |
To-BBB Technologies BV |
Leiden, the Netherlands |
8/30 |
€1.8 ($2.6) |
To-BBB closed a $2.6M second close of its Series B round, which was supported by a consortium of informal investors |
Tube Pharmaceuticals GmbH |
Vienna |
8/9 |
€1 ($1.4) |
Tube raised $1.4M in a seed funding round |
Vantia Therapeutics Ltd. |
London |
8/23 |
£8 ($13.1) |
Vantia raised $13.1M through funding from Novo Ventures and SV Life Sciences to form the new company KalVista Pharmaceuticals Ltd. |
Yaupon Therapeutics Inc. |
Radnor, Pa. |
8/15 |
$14.4 |
Yaupon raised $14.4M in a Series D round; investors were Vivo Ventures, Palo Alto Investors, Burril & Co. and Aperture Venture Partners |
|
||||
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |